Company Pulmatrix, Inc.

Equities

PULM

US74584P3010

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Delayed Nasdaq Other stock markets 18:20:45 30/04/2024 BST			5-day change	1st Jan Change
2 ^USD	+5.26%		-5.45%	+2.69%

03-28	Pulmatrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-13	Pulmatrix, Inc. Approves Termination of Margaret Wasilewski as Chief Medical Officer	CI

Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Companyâs proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as acute migraine and serious lung diseases, such as chronic obstructive pulmonary disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). The Companyâs product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes. The Companyâs therapeutic candidates include PUR3100, PUR1800, and PUR1900. PUR3100 is the iSPERSE formulation of dihydroergotamine (DHE), for the treatment of acute migraine.

Number of employees: 22

USD in Million	2022	Weight	2023	Weight	Delta
Novel Class of Inhaled Therapeutic Products 100.0 %	6	100.0 %	7	100.0 %	+20.21%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	6	100.0 %	7	100.0 %	+20.21%

Managers	Title	Age	Since
Teofilo Raad CEO	Chief Executive Officer	54	02/05/17
Peter Ludlum DFI	Director of Finance/CFO	68	17/04/22

Members of the board	Title	Age	Since
Richard Batycky BRD	Director/Board Member	56	31/10/19
Christopher Cabell BRD	Director/Board Member	54	22/06/20
Todd Bazemore BRD	Director/Board Member	53	30/09/20
Anand Varadan BRD	Director/Board Member	57	25/07/21
Teofilo Raad CEO	Chief Executive Officer	54	02/05/17
Michael Higgins CHM	Chairman	61	14/06/15

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	3,652,285	3,652,260 ( 100.00 %)	0	100.00 %

Name	Equities	%	Valuation
Renaissance Technologies LLC 3.212 %	117,321	3.212 %	205 312 $
BlackRock Institutional Trust Co. NA 1.503 %	54,900	1.503 %	96 075 $
Sabby Management LLC 1.484 %	54,188	1.484 %	94 829 $
Vanguard Group, Inc. (Subfiler) 0.9605 %	35,082	0.9605 %	61 394 $
Geode Capital Management LLC 0.6752 %	24,660	0.6752 %	43 155 $
STATE STREET CORPORATION 0.3818 %	13,945	0.3818 %	24 404 $
Tower Research Capital LLC 0.0977 %	3,570	0.0977 %	6 248 $
Securities America Advisors, Inc. 0.007557 %	276	0.007557 %	483 $
UBS Financial Services, Inc. 0.004518 %	165	0.004518 %	289 $
Wells Fargo Bank NA 0.000767 %	28	0.000767 %	49 $

Pulmatrix, Inc.

36 Crosby Drive Suite 100

01730, Bedford

+781 357 2333

http://www.pulmatrix.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
PULMATRIX, INC.	+2.69%	6.94M
VERTEX PHARMACEUTICALS INCORPORATED	-3.21%	102B
REGENERON PHARMACEUTICALS, INC.	+1.58%	96.29B
ARGENX SE	+2.13%	22.18B
BIONTECH SE	-15.72%	21.2B
GENMAB A/S	-9.21%	18.31B
WUXI APPTEC CO., LTD.	-39.98%	17.38B
BEIGENE, LTD.	-15.00%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+5.21%	13.97B
SAREPTA THERAPEUTICS, INC.	+33.67%	12.17B

Bio Therapeutic Drugs